Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy Academic Article uri icon

Overview

MeSH Major

  • Androstadienes
  • Fatigue
  • Prostatic Neoplasms
  • Taxoids

abstract

  • In patients with mCRPC progressing after docetaxel chemotherapy, abiraterone acetate and prednisone yielded clinically meaningful improvements in patient-reported fatigue compared with prednisone alone.

publication date

  • April 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/annonc/mds585

PubMed ID

  • 23152362

Additional Document Info

start page

  • 1017

end page

  • 25

volume

  • 24

number

  • 4